Prognostic significance of PAK family kinases in acute myeloid leukemia

Liang Quan, Zhiheng Cheng, Yifeng Dai, Yang Jiao, Jinlong Shi, Lin Fu*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Acute myeloid leukemia (AML) is a clonal and heterogeneous disease characterized by a myriad of genetic defects. Genetic abnormalities are powerful prognostic factors. P21-activated kinases (PAKs) are a kind of serine/threonine protein kinases, which is regulator of plenty of oncogenic signaling pathways. The clinical and prognostic value of PAKs in AML is unclear. A total of 155 AML patients with PAK expression data from The Cancer Genome Atlas database were enrolled in this study. Eighty-four patients underwent chemotherapy only, 71 also underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT). In the chemotherapy-only group, high PAK3 and PAK7 expression were both bound up with poor EFS and OS (all P < 0.05). However, high PAK2 expressers had better EFS and OS (all P < 0.05). Multivariate analysis demonstrated that high PAK7 expression was an adverse independent prognostic factor in patients who received chemotherapy only. PAKs have no influence in EFS and OS in patients who underwent allo-HSCT. In conclusion, high PAK2 expression is a favorable prognostic factor, as to the high expression of PAK3 and PAK7, they are poor prognostic factors, and PAK7 has better prognostic value, but their prognostic effects can be offset by allo-HSCT.

Original languageEnglish
Pages (from-to)30-37
Number of pages8
JournalCancer Gene Therapy
Volume27
Issue number1-2
DOIs
Publication statusPublished - 1 Feb 2020
Externally publishedYes

Fingerprint

Dive into the research topics of 'Prognostic significance of PAK family kinases in acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this